entertainment -WSS

entertainment

author：comprehensive 2025-09-14 08:27:04 - browse：94

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： My daughter's legacy lives on through her writing, phage therapy

hotspot

leisure time

WSS

Latigo launches with $135 million for Vertex

Report cites 'urgent' need to recruit more diverse clinical trial participants

Bernie Sanders gets little from pharma CEOs on drug prices

Pharma companies must ensure equitable access to obesity drugs

How faith leaders like me can help address America's obesity epidemic

New report analyzes digital physical therapy solutions' effectiveness

entertainment

entertainment

focus

Hepatitis C has a cure — but many Americans still lack access to it

Health care court cases: Humana, Sutter, Novant

Medical records are filled with copy

Report cites 'urgent' need to recruit more diverse clinical trial participants

Supreme Court strikes down use of affirmative action

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bernie Sanders gets little from pharma CEOs on drug prices

United colonoscopy coverage change 'may cost lives,' doctors say

New report analyzes digital physical therapy solutions' effectiveness

entertainment

Why Eli Lilly’s earnings didn’t quite live up to the hype

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Congress might make insulin pumps more accessible to the blind

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

California wildfire smoke linked to 52,000 early deaths, study says

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

hotspot

leisure time

explore

Wikipedia